Institution Directory

Clinical trials at Mayo Clinic

Sites in Rochester, MN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1818

Shown on this page

Current sort

Stored official records

Conditions: cGVHD
Interventions: Non-Interventional; Other
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 30 more

Conditions: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Interventions: Mosunetuzumab, Rituximab, Tocilizumab, Venetoclax; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 5
States / cities: Rochester, Minnesota • New York, New York • Columbus, Ohio + 2 more

Conditions: Aortic Aneurysm, Abdominal, Extent IV Thoracoabdominal, Juxtarenal Aortic Aneurysm, Pararenal Aneurysm
Interventions: Zenith Fenestrated+ Endovascular Graft in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System and Unibody2; Device
Lead sponsor: Cook Research Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 32
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 27 more

Conditions: Mitral Regurgitation, Mitral Valve Insufficiency
Interventions: SAPIEN M3 valve and dock; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 18 Years and older
Enrollment: 786 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 44
States / cities: Huntsville, Alabama • Phoenix, Arizona • La Jolla, California + 36 more

Conditions: Neurofibromatosis Type 1 (NF1), Plexiform Neurofibroma
Interventions: Mirdametinib (PD-0325901) oral capsule or dispersible tablet; Drug
Lead sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany; Industry
Eligibility: 2 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 37 more

Conditions: Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma
Interventions: Radiation Therapy, Temozolomide, Veliparib; Radiation · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 25 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 145
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 111 more

Conditions: Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Recurrent T Acute Lymphoblastic Leukemia, Recurrent T Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma, Refractory T Acute Lymphoblastic Leukemia, Refractory T Lymphoblastic Lymphoma
Interventions: Biospecimen Collection, Computed Tomography, Lumbar Puncture, Positron Emission Tomography, Venetoclax, Vincristine Liposomal, Vincristine Sulfate; Procedure · Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 163
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 120 more

Conditions: Refractory Hematologic Malignancy, Refractory Primary Central Nervous System Lymphoma, Relapsed Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma
Interventions: Emavusertib, Ibrutinib; Drug
Lead sponsor: Curis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 27
States / cities: Phoenix, Arizona • Duarte, California • Santa Monica, California + 19 more

Conditions: Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Wilms Tumor
Interventions: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, X-Ray Imaging; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 122
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 95 more

Conditions: Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow, Metastatic Malignant Neoplasm in the Lung, Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Interventions: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, External Beam Radiation Therapy, Ganitumab, Ifosfamide, Stereotactic Radiosurgery, Therapeutic Surgical Procedure, Vincristine, Vincristine Sulfate; Drug · Radiation · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 50 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 298
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 203 more

Conditions: Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor, Midgut Neuroendocrine Tumor G1, Neuroendocrine Tumor G2, Recurrent Digestive System Neuroendocrine Tumor G1, Regional Digestive System Neuroendocrine Tumor G1
Interventions: Biospecimen Collection, Computed Tomography, Echocardiography Test, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pazopanib Hydrochloride, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging; Procedure · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 412
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Anaheim, California + 263 more

Conditions: Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Resectable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Darizmetinib, Embolization Therapy, Hepatectomy, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

About this Mayo Clinic institution page

What this page lists: ClinicalTrials.gov records that list Mayo Clinic in Rochester, MN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Mayo Clinic

Filter and sort this campus

Stored official records

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Zenith® Fenestrated+ Clinical Study

The ENCIRCLE Trial

MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

About this Mayo Clinic institution page